This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-consensus: Archive
SKYX Platforms Corp. (SKYX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
SKYX PLATFORMS (SKYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SKYXPositive Net Change BTDRPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OBIOPositive Net Change ZYMENegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Ondas Holdings Inc. (ONDS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ondas (ONDS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ONDSNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OVIDPositive Net Change RNAPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOLTPositive Net Change PTGXNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FATEPositive Net Change ARCTNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
HIVE Digital Technologies (HIVE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
HIVE Digital Technologies (HIVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HIVEPositive Net Change WULFPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate CAE (CAE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CAE (CAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAEPositive Net Change DCOPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Evolution Petroleum (EPM) Reports Next Week: What You Should Expect
by Zacks Equity Research
Evolution Petroleum (EPM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EPMPositive Net Change MNRPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Opus Genetics, Inc. (IRD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRDPositive Net Change CERTPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts See a 29.89% Upside in Neogen (NEOG): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 29.9% upside potential for Neogen (NEOG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NEOGNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Rithm (RITM) Could Rally 27.73%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in Rithm (RITM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
RITMNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Atlassian (TEAM) Could Rally 33.64%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Atlassian (TEAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
TEAMPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does EverQuote (EVER) Have the Potential to Rally 48.01% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for EverQuote (EVER) points to a 48% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
EVERPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 33.9% Upside in Allegro MicroSystems (ALGM): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Allegro MicroSystems (ALGM) points to a 33.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ALGMPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 35.92% Upside in El Pollo Loco (LOCO): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 35.9% upside potential for El Pollo Loco (LOCO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LOCONegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Red Robin (RRGB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Red Robin (RRGB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RRGBNegative Net Change BLMNNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
StandardAero, Inc. (SARO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
StandardAero, Inc. (SARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAROPositive Net Change RDWPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate LivePerson (LPSN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LivePerson (LPSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LPSNPositive Net Change DASHPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Will 908 Devices Inc. (MASS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MASSNegative Net Change MTDNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Rocket Lab Corporation (RKLB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Rocket Lab Corporation (RKLB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RKLBPositive Net Change TDGPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Monday.com (MNDY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Monday.com (MNDY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MNDYNegative Net Change HUBSPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Will Energy Vault Holdings, Inc. (NRGV) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Energy Vault (NRGV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NRGVPositive Net Change TLNPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
The RealReal (REAL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
The RealReal (REAL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REALNegative Net Change IPARPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Guardian Pharmacy (GRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GRDNNegative Net Change NKTRNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate